BiotechTube

MVA-NP+M1 + Saline

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Mar 18, 2019 → Jan 21, 2020

NCT ID
NCT03880474

About MVA-NP+M1 + Saline

MVA-NP+M1 + Saline is a phase 2 stage product being developed by Barinthus Biotherapeutics for Influenza. The current trial status is terminated. This product is registered under clinical trial identifier NCT03880474. Target conditions include Influenza.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03880474Phase 2Terminated

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
VaccineComac MedicalPhase 3
69
CT-P27 90 mg/kg + CT-P27 45 mg/kg + PlaceboCelltrionPhase 2
52
CT-P27 + PlaceboCelltrionPhase 2
52
CAIV-TPfizerPhase 3
76
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
Baloxavir Marboxil + Placebo to Baloxavir Marboxil + Oseltamivir + Placebo to OseltamivirShionogiPhase 3
77
fH1 2 ug + fH1 8 ug + DSP-0546LP 2.5 ug + DSP-0546LP 5 ug + DSP-0546LP 10 ug + PlaceboSumitomo PharmaPhase 1
33
Monovalent Influenza VaccineAstraZenecaApproved
85
Monovalent Influenza VaccineAstraZenecaApproved
85
Trivalent Influenza VaccineAstraZenecaApproved
85
AZD4117 + AZD5315AstraZenecaPhase 1/2
41
Trivalent Influenza VaccineAstraZenecaApproved
85
FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
85
Trivalent Influenza Virus VaccineAstraZenecaApproved
85
Comparator: Modified Process Vaccine + Comparator: COMVAX™MerckPhase 3
77
Molnupiravir + Placebo molnupiravir + Placebo oseltamivir + Oseltamivir + Influenza A VirusMerckPhase 1
33
V512 + Comparator: Placebo to V512MerckPhase 1
33
Vaxelis + PedvaxHIBMerckApproved
85

Other Products from Barinthus Biotherapeutics

ChAdOx1-HBV + MVA-HBV + NivolumabPhase 2
44
Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloridePhase 2
44
MVA-NP+M1 + Saline + H3N2 (A/Belgium/2417/2015)Phase 2
44
ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]Phase 1/2
33
ChAdOx1-HPV + MVA-HPV + PlaceboPhase 1/2
33